Applications of (R)-N-Boc-3-Thienylalanine in Industrial Manufacturing

As a specialized manufacturer of (R)-N-Boc-3-Thienylalanine, we serve pharmaceutical and advanced chemical industries that require strict quality compliance and consistent enantiomeric purity. The following industrial application scenarios illustrate precise, documented uses of this chiral intermediate in commercial downstream production workflows.

1. Active Pharmaceutical Ingredient (API) Synthesis for Thienyl-Amino Acid–Based Drugs

Our (R)-N-Boc-3-Thienylalanine serves as a critical chiral intermediate during the synthesis of certain APIs incorporating thienylalanine motifs, notably for non-peptide enzyme inhibitors and receptor modulators. Process chemists employ this compound during advanced stage coupling reactions or as a protected building block in solid and solution-phase peptide synthesis, ensuring chirality transfer and minimizing racemization in regulated pharmaceutical environments.

Industry compliance standards

• ICH Q7 and Q11 GMP guidelines for API manufacturing
• USP/EP/JP monograph criteria for enantiomeric purity and residual solvents
• EMA and FDA Part 211 cGMP requirements
• Certificate of Suitability (CEP) submission frameworks

Typical usage ratio

• Employed at 1:1 molar ratio with target amine or acid reactants in API assembly steps; precise level controlled to limit excess and optimize chiral yield

Downstream process integration

• Added post-initial precursor synthesis, pre-coupling step, or during N-terminal elongation under controlled temperature and pH for peptide and non-peptide API assembly

Final product types

• Orally active enzyme inhibitors in tablet or capsule form
• Thienylalanine-derived receptor modulators as finished APIs for licensed medicines
• Chiral pharmaceutical intermediates for further downstream transformations

2. Peptide Synthesis for Preclinical and Clinical Drug Development

Several biopharmaceutical manufacturers and contract research organizations employ this protected thienylalanine derivative in automated and manual solid-phase peptide synthesis (SPPS) protocols to build lead candidates and peptide-based APIs. Its high enantiopurity and stable Boc protection facilitate selective incorporation at defined sequence positions, supporting lead optimization and SAR studies in peptide drug pipelines.

Industry compliance standards

• GMP standards specific to peptide manufacturing (ICH Q7, US FDA 21 CFR Part 210/211)
• USP <1047> compliance for peptide purity and identity
• EMA “Guideline on the quality of synthetic peptide–based drugs” (EMA/CHMP/QWP/104823/2006)
• Applicable local pharmacopoeias and quality management systems (ISO 9001, ISO 13485)

Typical usage ratio

• Standard load of 0.9–1.1 equivalents per coupling cycle on resin, adjusted for resin substitution levels and sequence length to control chain assembly

Downstream process integration

• Direct loading onto peptide resin following Fmoc/Boc deprotection cycles using HBTU, HATU, or phosphonium coupling reagents at monitored conditions to maintain stereochemistry

Final product types

• Research-grade peptide libraries for in vitro screening
• Preclinical peptide drug candidates for IND-enabling studies
• Custom chiral peptides for CGMP-compliant pilot drug batches

3. Custom Chiral Building Block for Agrochemical Discovery

In agrochemical R&D, chemists integrate enantiopure thienylalanine derivatives as custom chiral blocks for structure–activity relationship screening, expanding the structural diversity of fungicide and insecticide candidates. The Boc-protected format supports reliable integration into existing synthetic routes, with downstream deprotection enabling rapid analog synthesis.

Industry compliance standards

• OECD Principles of Good Laboratory Practice (GLP) for discovery and safety evaluation
• ISO 9001:2015 for chemical substance manufacturing quality
• Region-specific pesticide registration guidelines (e.g., EPA OPPTS 830, EU Regulation 1107/2009)
• Internal agrochemical company supply chain validation (audits, CoA requirements)

Typical usage ratio

• Adopted at 0.2–0.8 molar equivalents per target heterocyclic intermediate; varying with desired level of chiral induction and structural analog diversity

Downstream process integration

• Introduced during key coupling reactions in lead structure assembly or during late-stage functionalization for SAR optimization

Final product types

• New-to-world candidate agrochemicals for patent investigation
• Advanced lead compounds for pilot biological evaluation
• Reference standards for regulatory submission and impurity profiling

4. Chiral Auxiliary in Advanced Asymmetric Synthesis

Manufacturers specialized in high-value fine chemicals and pharmaceutical intermediates use this compound as a chiral auxiliary to introduce and control stereochemistry in complex molecule synthesis. Its steric and electronic properties provide effective asymmetric induction in transition metal-catalyzed or organocatalytic reactions, underpinning scalable synthesis of target enantiomers with minimal byproduct formation.

Industry compliance standards

• GMP/ICH Q11 for intermediates in active ingredient production
• ISO 9001:2015 certification for contract fine chemical manufacturing
• Company-specific supply quality agreements for auxiliary use
• Documentation per EU REACH regulations for substance handling and traceability

Typical usage ratio

• Applied between 0.5 and 1.5 equivalents relative to prochiral substrate depending on the reaction pathway and recycling strategies for the auxiliary

Downstream process integration

• Introduced at the chiral induction step, typically preceding further transformation or auxiliary cleavage to yield the enantioenriched target molecule

Final product types

• Enantiomerically pure specialty chemicals for pharmaceutical and fine chemical use
• Chiral advanced intermediates for downstream contract manufacturing
• Complex synthetic building blocks for library generation and process development